Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7922 USD | +0.28% | +5.36% | +6.62% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.62% | 43.19M | C- | ||
-2.47% | 88.14B | A- | ||
+3.29% | 40.44B | A- | ||
-15.40% | 32.24B | B- | ||
+51.96% | 24.39B | A | ||
-14.35% | 15.59B | C | ||
-39.65% | 12.3B | B | ||
-6.52% | 12.18B | D+ | ||
-13.41% | 12.14B | B- | ||
+5.17% | 8.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CARA Stock
- Ratings Cara Therapeutics, Inc.